Ikić D

APPLICATION OF HUMAN LEUCOCYTE INTERFERON IN PATIENTS WITH URINARY BLADDER PAPILLOMATOSIS, BREAST CANCER, AND MELANOMA

Eight patients with malignant papillomaosis of the bladder, four with breast cancer, and two with malignant melanoma, all of whom had a poor prognosis, were treated with injection of crude human leucocyte interferon (HLI) into the tumour or the adjacent tissue and in some cases with intramuscular HLI injection also. All tumours showed complete or partial regression after treatment for up to 6 months. One patient with breast cancer died from distant metastases; all other patients in the trial were recurrence-free after 3--30 months of follow-up.

APPLICATION OF HUMAN LEUCOCYTE INTERFERON IN PATIENTS WITH CARCINOMA OF THE UTERINE CERVIX

15 patients with invasive squamous-cell carcinoma of the uterine cervix were treated with crude human leucocyte interferon (HLI) for 3 weeks before surgical removal of the tumour. 9 patients were given HLI topically and intramuscularly and 6 topically only. In 3 patients the surgical material was free from tumour cells, in 3 it showed a lower grade of carcinoma, and in 9 the findings remained unchanged. In only 1 patient the tumour metastasised to the lymph nodes. Typically a tumour regressed to about a third of its original size. There was a sharp distinction between the tumour mass and the healthy tissue manifested in the formation of a fibrous wall. On the basis of the scores--i.e., stromal response, relation between tumour-cell and macrophage activity and reactivity, and reactivity of the original lymph nodes--the overall appraisal of the response caused by HLI therapy was as follows: in 6 patients excellent, in 5 very good, in 1 moderate, in 2 poor, and in 1 no response. It is suggested that HLI is suitable for administration both before and after surgery in patients with cervical cancer of grade I or II. If stroma cannot be induced to respond within 21 days of treatment, HLI application should be discontinued.

Effect of interferon in therapy of skin and head and neck tumors

SummaryThe clinical experimental model of HLI application in the therapy of skin and mucosal cancers of the head and neck has opened new prospects in HLI utilization. Based on clinical observations and research in may be concluded that HLI, if applied topically in the area of the tumor, may induced its disappearance or regression. If applied presurgically, it blocks the dispersion of neocytes during surgery. Also, HLI inhibits metastatic dissemination of malignant tumors and therefore might reduce the percentage of patients with recurrence, decreasing the chance of survival of any other primary tumor.

APPLICATION OF HUMAN LEUCOCYTE INTERFERON IN PATIENTS WITH TUMOURS OF THE HEAD AND NECK

Local administration of crude human leucocyte interferon (HLI) produced substantial or total remission in patients with cancers of the head and neck. At the end of HLI therapy 10 of 30 patients were considered completely cured. In 10 patients unepithelialised skin lesions were hardly visible, in 5 the tumours were significantly reduced in size and had clear-cut borders, in 2 the tumours showed a tendency towards regression, and in 3 there was no effect. Application of HLI close to the tumour site appears to prevent dispersal of tumour cells during surgical removal of the tumour. It also inhibits metastatic spread, thereby reducing the likelihood of recurrence.

Treatment of Squamous Cell Carcinoma with Interferon

ABSTRACT: Human natural leukocytic interferon and recombinant HulFN alpha 2c can be used in the therapy of squamous cell carcinoma. The duration of treatment was 3‐6 weeks. A single dose was 400,000‐5,000,000 units given weekly for 3‐6 weeks. Clinically and histologically 19 of 32 patients were cured and tumor cells were not found in the material taken after interferon treatment for the second biopsy. In ten patients tumor size was reduced 25‐90%, and in three patients tumor size was not reduced according to clinical findings. With recombinant HulFN alpha 2c therapy given 5 times per week for 4 weeks. Four of ten patients with similar tumors were cured clinically and histologically clinical findings. In five patients tumor size was reduced 25–90%, while in one patient there was no reduction in tumor size. Both types of interferons are effective in the treatment of squamous cell carcinoma. Side reactions were mild.

INTERFERON REDUCES RECURRENCES OF BASAL CELL AND SQUAMOUS CELL CANCERS

Background.Interferon is considered to be an important curative agent for dermatologic diseases. We report the follow‐up experience of patients with basal cell or squamous cell carcinomas treated with human natural leukocyte interferon (hnli).

Interferon treatment of uterine cervical precancerosis

SummaryHuman leukocyte interferon (HLI) was used in a randomized study of patients with precancerous states on the uterine cervix. The daily dose of HLI was 106 units and it was applied by the contraceptive pessary technique. In patients who had had only viral alterations on the cervix the treatment lasted 14 days (Singer et al. 1979) and in those with changed cytologic findings 21 days.The cytologic findings of the interferon treated patients showed no progression of the pathologic process during the ensuing 2 years. In the control group, however, they showed the aggravation of the process and the patients were directed to surgical therapy.The control of cytologic findings has been continued and is now performed at 3 month intervals.

LOCAL INTERFERON THERAPY FOR MELANOMA PATIENTS

Background. Melanoma, once considered a rare form of cancer, is increasing in incidence throughout the world. The prognosis of malignant melanoma is inversely related to the depth of tumor invasion.

Human leukocyte interferon in therapy of patients with urinary bladder papillomatosis, breast cancer, and melanoma

SummaryThe authors report the results of local and parenteral applications of human leukocyte crude interferon in the therapy of eight patients with urinary bladder papillomatosis, four patients with breast cancer, and two patients with melanoma. The doses and effects of treatment are presented in tables. Clinical application of human leukocyte interferon (HLI) to these three types of malignant tumors has yielded encouraging results. The authors believe that investigations on HLI applications to some malignant tumors should continue because the results obtained indicate that interferon possesses not only an antiviral but also an antitumor activity.

Local interferon therapy for lip carcinoma

In a prospective non-randomized study 21 patients with lower lip squamous cell carcinoma were treated with human natural leukocyte interferon (HNLI). The response rate was measured by a size reduction of more than 25% and was 81%. A complete response rate was considered to be a cure according to histopathological and clinical findings and was 48%. The response rate of six lower lip squamous cell carcinoma cases treated with recombinant interferon alpha 2c was 67% and the complete response rate was 17%. Three patients with basal cell carcinoma of the upper lip were also treated with HNLI. All three patients were cured, as determined by histopathological and clinical findings. These findings indicate that interferon can be a useful alternative therapy for lip carcinoma either with or without surgery.